N-(3-morpholinopropyl)-4-nitrobenzamide | 14443-42-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-morpholinopropyl)-4-nitrobenzamide
• 英文别名: N-(3-morpholin-4-yl-propyl)-4-nitro-benzamide；N-(3-morpholin-4-ylpropyl)-4-nitrobenzamide
• CAS: 14443-42-6
• 化学式: C₁₄H₁₉N₃O₄
• 分子量: 293.323
• InChiKey: ZEWOVHOFRWMQPJ-UHFFFAOYSA-N

物化性质

• 沸点：
  512.8±45.0 °C(Predicted)
• 密度：
  1.226±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  87.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(3-morpholinopropyl)-4-nitrobenzamide 在 吡啶 、 mercury(II) diacetate 、 铁粉 、 碳酸氢钠 、 氯化铵 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 15.5h， 生成 4-((5-(4-cyanothiophen-2-yl)-1,3,4-oxadiazol-2-yl)amino)-N-(3-morpholinopropyl)benzamide
  参考文献：
  名称：

  Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model

  摘要：

  FLT3 mutation is among the most common genetic mutations in acute myeloid leukemia (AML), which is also related with poor overall survival and refractory in AML patients. Recently, FLT3 inhibitors have been approved for AML therapy. Herein, a series of new compounds with pyrazole amine scaffold was discovered, which showed potent inhibitory activity against FLT3-ITD and significant selectivity against both FLT3-ITD and AML cells expressing FLT3-ITD. Compound 46, possessing the most promising cellular activity, blocked the autophosphorylation of FLT3 pathway in MV4-11 cell line. Furthermore, the apoptosis and downregulation of P-STAT5 were also observed in tumor cells extracted from the MV411 cell xenografts model upon compound 46 treatment. Compound 46 was also metabolically stable in vitro and suppressed tumor growth significantly in MV4-11 xenografts model in vivo. Compound 46 showed no toxicity to the viscera of mice and caused no decrease in body weight of mice. In conclusion, the results of this study could provide valuable insights into discovery of new FLT3 inhibitors, and compound 46 was worthy of further development as potential drug candidate to treat AML (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.05.021
• 作为产物：
  描述：

  N-(3-氨丙基)吗啉 、 对硝基苯甲酸 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.25h， 以29%的产率得到N-(3-morpholinopropyl)-4-nitrobenzamide
  参考文献：
  名称：

  鉴定新型 2,4,5-三取代嘧啶作为具有体外抗血期寄生虫活性的血浆 PfGSK3/PfPK6 的强效双重抑制剂

  摘要：

  必需的疟原虫激酶Pf GSK3 和Pf PK6 被认为是新的药物靶点，可对抗对传统抗疟治疗不断上升的耐药性。在此，我们报告了IKK16作为Pf GSK3/ Pf PK6 双重抑制剂的发现，对血液阶段Pf 3D7 寄生虫具有活性。为了建立Pf PK6 和Pf GSK3 的构效关系，合成了 52 种类似物并评估了对Pf GSK3 和Pf PK6 的抑制作用，并进一步评估了强效抑制剂对血液和肝脏阶段寄生虫的活性。这最终导致发现了双Pf GSK3/Pf PK6 抑制剂23d ( Pf GSK3/ Pf PK6 IC 50 = 172/11 nM) 和23e ( Pf GSK3/ Pf PK6 IC 50 = 97/8 nM) 具有抗疟原虫活性 ( 23d Pf 3D7 EC 50 = 552 ± 37 nM 和23e Pf 3D7 EC 50 = 1400 ± 13 nM)。然而，当在一组人类激酶

  DOI：

  10.1021/acs.jmedchem.2c00996

文献信息

• Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model
  作者：Hao Heng、Zhijie Wang、Hongmei Li、Yatian Huang、Qingyuan Lan、Xiaoxing Guo、Liang Zhang、Yanle Zhi、Jiongheng Cai、Tianren Qin、Li Xiang、Shuxian Wang、Yadong Chen、Tao Lu、Shuai Lu

  DOI：10.1016/j.ejmech.2019.05.021

  日期：2019.8

  FLT3 mutation is among the most common genetic mutations in acute myeloid leukemia (AML), which is also related with poor overall survival and refractory in AML patients. Recently, FLT3 inhibitors have been approved for AML therapy. Herein, a series of new compounds with pyrazole amine scaffold was discovered, which showed potent inhibitory activity against FLT3-ITD and significant selectivity against both FLT3-ITD and AML cells expressing FLT3-ITD. Compound 46, possessing the most promising cellular activity, blocked the autophosphorylation of FLT3 pathway in MV4-11 cell line. Furthermore, the apoptosis and downregulation of P-STAT5 were also observed in tumor cells extracted from the MV411 cell xenografts model upon compound 46 treatment. Compound 46 was also metabolically stable in vitro and suppressed tumor growth significantly in MV4-11 xenografts model in vivo. Compound 46 showed no toxicity to the viscera of mice and caused no decrease in body weight of mice. In conclusion, the results of this study could provide valuable insights into discovery of new FLT3 inhibitors, and compound 46 was worthy of further development as potential drug candidate to treat AML (C) 2019 Elsevier Masson SAS. All rights reserved.
• Identification of Novel 2,4,5-Trisubstituted Pyrimidines as Potent Dual Inhibitors of Plasmodial <i>Pf</i>GSK3/<i>Pf</i>PK6 with Activity against Blood Stage Parasites In Vitro
  作者：Kareem A. Galal、Anna Truong、Frank Kwarcinski、Chandi de Silva、Krisha Avalani、Tammy M. Havener、Michael E. Chirgwin、Eric Merten、Han Wee Ong、Caleb Willis、Ahmad Abdelwaly、Mohamed A. Helal、Emily R. Derbyshire、Reena Zutshi、David H. Drewry

  DOI：10.1021/acs.jmedchem.2c00996

  日期：2022.10.13

  PfGSK3 and PfPK6, with potent inhibitors further assessed for activity against blood and liver stage parasites. This culminated in the discovery of dual PfGSK3/PfPK6 inhibitors 23d (PfGSK3/PfPK6 IC50 = 172/11 nM) and 23e (PfGSK3/PfPK6 IC50 = 97/8 nM) with antiplasmodial activity (23dPf3D7 EC50 = 552 ± 37 nM and 23ePf3D7 EC50 = 1400 ± 13 nM). However, both compounds exhibited significant promiscuity when

  必需的疟原虫激酶Pf GSK3 和Pf PK6 被认为是新的药物靶点，可对抗对传统抗疟治疗不断上升的耐药性。在此，我们报告了IKK16作为Pf GSK3/ Pf PK6 双重抑制剂的发现，对血液阶段Pf 3D7 寄生虫具有活性。为了建立Pf PK6 和Pf GSK3 的构效关系，合成了 52 种类似物并评估了对Pf GSK3 和Pf PK6 的抑制作用，并进一步评估了强效抑制剂对血液和肝脏阶段寄生虫的活性。这最终导致发现了双Pf GSK3/Pf PK6 抑制剂23d ( Pf GSK3/ Pf PK6 IC 50 = 172/11 nM) 和23e ( Pf GSK3/ Pf PK6 IC 50 = 97/8 nM) 具有抗疟原虫活性 ( 23d Pf 3D7 EC 50 = 552 ± 37 nM 和23e Pf 3D7 EC 50 = 1400 ± 13 nM)。然而，当在一组人类激酶